Evidence map›Paper›PMID 32895277›Full record

ReviewBMJ open2020

Critical review of multimorbidity outcome measures suitable for low-income and middle-income country settings: perspectives from the Global Alliance for Chronic Diseases (GACD) researchers.

John R Hurst, Gina Agarwal, Job F M van Boven, Meena Daivadanam, Gillian Sandra Gould, Erick Wan-Chun Huang, Pallab K Maulik, J Jaime Miranda, M O Owolabi, Shahirose Sadrudin Premji and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in BMJ open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

John R HurstUCL Respiratory, University College London, London, UK j.hurst@ucl.ac.uk.ORCID 0000-0002-7246-6040
Gina AgarwalFamily Medicine, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0002-5691-4675
Job F M van BovenDepartment of Clinical Pharmacy & Pharmacology, University Medical Center Groningen, Groningen, The Netherlands.ORCID 0000-0003-2368-2262
Meena DaivadanamDeptartment of Global Public Health, Karolinska Institutet, Stockholm, Sweden.
Gillian Sandra GouldSchool of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia.ORCID 0000-0001-8489-2576
Erick Wan-Chun HuangRespiratory and Environmental Epidemiology, Woolcock Institute of Medical Research, Sydney, New South Wales, Australia.
Pallab K MaulikResearch, The George Institute for Global Health, New Delhi, India.
J Jaime MirandaCRONICAS Centre of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru.ORCID 0000-0002-4738-5468
M O OwolabiMedicine, University of Ibadan College of Medicine, Ibadan, Nigeria.ORCID 0000-0003-1146-3070
Shahirose Sadrudin PremjiSchool of Nursing, Faculty of Health, York University, Toronto, Ontario, Canada.
Joan B SorianoUniversidad Autónoma de Madrid, Madrid, Spain.
Rajesh VedanthanDepartment of Population Health and Department of Medicine, NYU Langone Health, New York, New York, USA.
Lijing YanGlobal Health Research Center, Duke Kunshan University, Jiangsu, China.
Naomi LevittMedicine, University of Cape Town, Cape town, South Africa.
GACD Multi-Morbidity Working Group

Funding

Medical Research Council MR/P008984/1
6 · The paper itself

Abstract

objectivesThere is growing recognition around the importance of multimorbidity in low-income and middle-income country (LMIC) settings, and specifically the need for pragmatic intervention studies to reduce the risk of developing multimorbidity, and of mitigating the complications and progression of multimorbidity in LMICs. One of many challenges in completing such research has been the selection of appropriate outcomes measures. A 2018 Delphi exercise to develop a core-outcome set for multimorbidity research did not specifically address the challenges of multimorbidity in LMICs where the global burden is greatest, patterns of disease often differ and health systems are frequently fragmented. We, therefore, aimed to summarise and critically review outcome measures suitable for studies investigating mitigation of multimorbidity in LMIC settings.

settingLMIC.

participantsPeople with multimorbidity. OUTCOME MEASURES: Identification of all outcome measures.

resultsWe present a critical review of outcome measures across eight domains: mortality, quality of life, function, health economics, healthcare access and utilisation, treatment burden, measures of 'Healthy Living' and self-efficacy and social functioning.

conclusionsStudies in multimorbidity are necessarily diverse and thus different outcome measures will be appropriate for different study designs. Presenting the diversity of outcome measures across domains should provide a useful summary for researchers, encourage the use of multiple domains in multimorbidity research, and provoke debate and progress in the field.

Indexed as

MultimorbidityQuality of LifeChronic DiseaseHumansOutcome Assessment, Health CarePovertyclinical trialsprimary carepublic healthstatistics & research methods

Identifiers

PMID32895277
PMCPMC7478040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.